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DonorT-cell mediated graft versus host (GVH) effects may result from the aggregate allore-
activity to minor histocompatibility antigens (mHA) presented by the human leukocyte
antigen (HLA) molecules in each donor–recipient pair undergoing stem-cell transplantation
(SCT). Whole exome sequencing has previously demonstrated a large number of non-
synonymous single nucleotide polymorphisms (SNP) present in HLA-matched recipients
of SCT donors (GVH direction). The nucleotide sequence flanking each of these SNPs was
obtained and the amino acid sequence determined. All the possible nonameric peptides
incorporating the variant amino acid resulting from these SNPs were interrogated in sil-
ico for their likelihood to be presented by the HLA class I molecules using the Immune
Epitope Database stabilized matrix method (SMM) and NetMHCpan algorithms.The SMM
algorithm predicted that a median of 18,396 peptides weakly bound HLA class I molecules
in individual SCT recipients, and 2,254 peptides displayed strong binding. A similar library
of presented peptides was identified when the data were interrogated using the NetMHC-
pan algorithm. The bioinformatic algorithm presented here demonstrates that there may
be a high level of mHA variation in HLA-matched individuals, constituting a HLA-specific
alloreactivity potential.
Keywords: alloreactivity potential, stem-cell transplant, whole exome sequencing, HLA, minor histocompatibility
antigen
INTRODUCTION
Graft versus host disease (GVHD) is a major impediment in
achieving optimal outcomes in patients undergoing allogeneic
stem-cell transplantation (SCT) from human leukocyte antigen
(HLA) identical related and unrelated donors (URD) (1–3). Fur-
ther, it remains unclear why with only relatively minor variation
in GVHD prophylaxis, some patients with HLA-matched donors
develop severe GVHD, whilst others with HLA-mismatched
donors may not experience any (4–6). In HLA-matched donor-
recipient pairs (DRP), a major contributor to GVHD occurrence
are the peptides encoded by loci outside the major histocom-
patibility (MHC) locus on chromosome 6. These peptides, func-
tionally defined as minor histocompatibility antigens (mHA), are
presented by specific HLA molecules and are responsible for both
the clinically beneficial graft versus tumor responses, and the dele-
terious GVHD (7–10). As of 2012, around 49 mHA recognized by
CD4+ or CD8+ T lymphocytes have been described (11). Fur-
ther complicating this problem is the HLA specificity of various
mHA, and the heterogeneity observed in the HLA distribution in
various populations across the world (12, 13). Therefore, in order
to understand the biology and role of mHA in generating GVHD,
it is critical to quantify the extent of genetic variation between
individuals.
Exploring genetic variation outside the MHC locus is also
important to understand why, with relatively simple adjustments
to the treatment protocols patients successfully engraft when
transplanted with HLA-mismatched donors. This is true for both
URD umbilical cord blood transplant, and related haploidenti-
cal SCT (6). Moreover, completely HLA-mismatched solid organ
transplants result in successful engraftment, albeit with low-level
life-long immunosuppression. Furthermore, organs, such as kid-
ney and heart tissues, are prone to rejection when transplanted;
yet, these organs are seldom targeted in GVHD, even in its chronic
form, which affects nearly all organ systems. This makes it impera-
tive to understand the role of mHA in generating alloreactivity, and
the extent to which the magnitude of genetic variation outside the
MHC locus contributes to allograft complications, such as GVHD
or graft rejection.
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To examine these quantitative relationships, whole exome
sequencing of SCT donor and recipients genomes was performed
to measure the antigenic variability existing between them (14).
A large number of single nucleotide polymorphisms (SNP) were
identified between donors and recipients. These differences were
classified as, either possessing, a GVH vector, polymorphisms
present at loci in the recipient and absent in the donor, or, a
HVG vector, present in the donor and absent in the recipient.
The large number of SNPs in the exome, termed alloreactivity
potential, suggests that in all individuals undergoing SCT, there is
a very high probability of there being peptides, which may func-
tion as mHA. However, given the observed frequency of GVHD,
seemingly, not all of these SNPs would lead to immunogenic pep-
tides being generated, to yield clinically relevant mHA responses.
This may be because, for HLA class I molecules on an antigen-
presenting cell to present a peptide to an effector T lymphocyte,
first, the endogenous protein must be cleaved by the proteasome,
then the resulting peptides must bind HLA class I molecules to
be presented. This would initiate either an immune response or
result in tolerance, depending on the cellular and cytokine milieu
at the time of antigen presentation (15).
It is possible to determine the genetic variation between SCT
recipients and donors, and to then bioinformatically determine
the amino acid sequence of peptides resulting from SNPs encoun-
tered in their exomes. Further, bioinformatic techniques have been
developed to determine which peptide antigens may be presented
by specific HLA molecules. The Immune Epitope Database (IEDB;
http://www.iedb.org) has characterized hundreds of thousands of
peptides that can bind several hundred MHC complexes. From this
large dataset, researchers have developed tools to predict peptide-
HLA binding probabilities (16). Initially, matrix-based methods
such as stabilized matrix method (SMM) (17) were developed to
determine binding affinities. More recently, neural network-based
algorithms such as NetMHC can use binding information from
neighboring residues to predict dissociation constants between
HLA molecules and putative mHA (18). Finally, “pan-specific”
algorithms have developed that are able to predict peptide-binding
HLA alleles with limited experimental binding data (19).
In this paper, the putative mHA in HLA-matched DRP and
the in silico determined HLA class I binding affinity of these
peptides is explored utilizing a bioinformatic approach based on
exome sequencing of donors and recipients of SCT. The algo-
rithm developed, lays a framework for future analysis of large SCT
patient cohorts, and defines a personalized HLA-specific alloreac-
tivity potential. The alloreactivity potential concept is analogous
to the idea of potential energy in physics, i.e., the stored energy
in a system. Thus, HLA-specific alloreactivity potential would give
an estimate of the likelihood that GVHD or graft rejection may
develop in a HLA-matched DRP in the absence of immunosup-
pression. Our work demonstrates that the number of potentially
immunogenic peptides varies considerably across HLA-matched
related (MR) and URD,constituting a large alloreactivity potential.
METHODS
WHOLE EXOME SEQUENCING
Patients with recurrent hematological malignancies enrolled in a
Virginia Commonwealth University Institutional Review Board
Table 1 | HLA typing of the donor–recipient pairs.
D-RPair HLA-A HLA-A HLA-B HLA-B HLA-C HLA-C
2 02:01 24:02 15:16 27:05 02:02 17:01
3 03:01 11:01 07:02 55:01 03:03 07:02
4 23:01 30:02 15:03 44:03 02:10 07:18
5 01:01 03:01 570101 07:02 07:02 07:01
7 01:01 02:01 44:02 55:01 03:03 05:01
8 01:01 24:02 07:02 55:01 03:03 07:02
10 01:01 03:01 080101 40:01 03:04 07:01
16 01:01 26:01 13:02 27:05 02:02 06:02
23 03:01 24:02 07:02 57:01 06:02 07:02
Patients 2, 4, 16, and 23 underwent MRD and the others URD SCT. Patient 2
had a single locus HLA-B antigen mismatch; patients 3, 7, and 10 had a male
donor/female recipient combination and others were gender matched.
approved protocol (Clinicaltrial.gov identifier: NCT00709592)
were included in this study. To identify all the potentially immuno-
genic differences that exist in a SCT DRP, whole exome sequencing
was performed on previously cryopreserved DNA from the donors
and recipients enrolled in this study as previously described (14).
Of the nine DRP examined, four were from HLA-A, B, C, and
DRB1 MRD, and 5 from URD. Histocompatibility testing was
performed using high-resolution typing for both HLA class I
(Table 1) and HLA class II loci (not shown). The whole exome
sequence of individual donors and recipients was compared both
within pairs, and to a reference genome to identify all the SNPs,
which were subsequently characterized as either synonymous or
non-synonymous. Next, all the non-synonymous SNP (nsSNP)
present in the recipient, but absent in the donor were identified,
and designated as possessing a graft versus host (GVH) vector
(nsSNPGVH).
DERIVING HLA-SPECIFIC ALLOREACTIVITY POTENTIAL
To derive the amino acid sequence of the oligopeptides, i.e., poten-
tial mHA, resulting from these nsSNPs and their binding affinity
to the relevant HLA in each DRP, a bioinformatics pipeline was
developed. This pipeline has the following components: (1) deter-
mine nsSNPGVH between the exomes of transplant donors and
recipients; (2) generate putative immunogenic peptides in sil-
ico from these genomic differences; and (3) analyze the binding
affinity of these polymorphic peptides to the HLA in that indi-
vidual (Figure 1). This third step estimates the likelihood of these
peptides to be presented by the six patient-specific HLA class I
molecules to determine candidate mHA. A complete description
of this bioinformatic pipeline follows.
CREATION OF PEPTIDE LIBRARIES
All the nsSNPGVH for each DRP were exported as variant call files
(VCF) to the ANNOVAR software package (20). Next,using the DB
SNP130 database and hg18 genome coordinates of the nsSNPGVH,
amino acid sequences of the putative peptides were generated
using the “seq_padding” option of the “annotate_variation” func-
tion in ANNOVAR. Endogenous peptides are presented by HLA
class I molecules, and the average length of peptides binding HLA
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FIGURE 1 | Bioinformatics workflow for calculating HLA-specific
alloreactivity potential in individual DRP. Starting with donor and recipient
whole exome sequence data, non-synonymous SNP with a GVH vector
(nsSNPGVH) were identified, and peptide fragments generated using the
ANNOVAR software package. These peptides, together with HLA data
(Table 1) were then analyzed with IEDB SMM and NetMHCpan algorithms
separately. Individual DRP binding data were then analyzed and candidate
mHAs cataloged.
class I is 9 amino acids. Therefore, for each polymorphism,ANNO-
VAR returned 8 amino acids on either side of the nsSNPGVH-
encoded amino acid, resulting in a 17-mer peptide. This effectively
generated nine nonamers from each nsSNPGVH-encoded poly-
morphism; thus, the resulting peptides would have the polymor-
phic amino acid at positions 1 to 9, from the C- to the N-terminal
position (Figure 1).
IN SILICO VARIANT PEPTIDE-HLA BINDING AFFINITY DETERMINATION
The 17-mer peptides generated by ANNOVAR resulting from
the nsSNPGVH were analyzed by the IEDB-MHC I-peptide bind-
ing prediction tools version 2.9.1, downloaded from (http://tools.
immuneepitope.org/analyze/html_mhcibinding20090901B/down
load_mhc_I_binding.html). Nine oligopeptides were created for
each 17-mer peptide using a 9-mer sliding window. The bind-
ing affinity of each of these 9-mers to the patient-specific HLA-A,
HLA-B, and HLA-C (Table 1) were determined by running each 9-
mer independently through the IEDB-MHC I prediction software.
The output of this iterative process included variables, such as, the
gene name and coordinates, the polymorphic peptide sequence,
and the calculated IC50 value via the SMM algorithm (a partial
example of output in Table S1 in Supplementary Material). IC50
values in nano-Molar (nM) represent the concentration of the
test peptide, which will displace 50% of a standard peptide from
the HLA molecule in question. The lower the IC50 for a peptide,
the stronger the binding affinity of that peptide for the HLA in
question. The cutoff in our analysis to classify a putative peptide
as being presented by HLA, is an IC50 of <500 nM (intermedi-
ate affinity binding; http://tools.immuneepitope.org/mhci/help/).
Those peptides that bound to HLA with an IC50 of <50 nM were
designated strongly presented (high affinity binding).
To validate the findings from the SMM algorithm, the ANNO-
VAR generated 17-mer peptide libraries were next interrogated
using the NetMHCpan software (http://www.cbs.dtu.dk/services/
NetMHCpan/). To accomplish this, two software programs were
developed to analyze the peptide data and query NetMHCpan
remotely. The first program sequentially sent packets of 30 pro-
tein sequences to NetMHCpan. The protein sequences were sent in
order by patient and HLA,and a sliding 9-mer window was selected
to interrogate HLA binding, similar to SMM IEDB algorithm.
NetMHC then returned html results, which were then stored on
the local server. The second program examined the returned html
results and organized it in a comma-separated-value (.csv) file,
which could then be opened in Microsoft Excel for further analysis.
Results from the SMM IEDB algorithm and NetMHCpan were
compared in each DRP by HLA loci and polymorphic peptides.
Specifically, HLA locus and polymorphic peptide were combined
to make a single variable within each patient dataset, allowing for
the removal of duplicate peptides and identification of unique
polymorphic peptides found by both or one methods. Presented
and strongly presented polymorphic peptides were compared
between the two methods, and then combined to get a compre-
hensive list of unique polymorphic peptide-HLA complexes for
each patient.
DERIVING HLA-SPECIFIC ALLOREACTIVITY POTENTIAL
Given the large number of peptides strongly binding HLA identi-
fied in each DRP, area under the curve for the IC50 of the strongly
binding peptides was determined to summarize the data. The
peptide-HLA IC50s were plotted in an ascending order (descend-
ing order of affinity). First the non-linear distribution function
of the peptides up to an IC50 of 100 nM was computed (a poly-
nomial function of the second order). To obtain the area under
the curve depicting the peptide-HLA complexes and their corre-
sponding dissociation constants, the definite integral of the curve
was determined. The definite integral by definition is the area of
the x–y plane bounded by the curve Eq. (1),∫ b
a
f (x) dx (1)
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FIGURE 2 |The burden of minor histoincompatibility in human SCT.
(A) All possible mHA in human beings: data generated from NCBI dbSNP
database (22). (B) Alloreactivity potential: the current patient cohort had an
average of 6,445 nsSNPs/DRP, which when converted into peptide fragments
averaged 486,463 possible mHA/DRP. (C) Putative mHA: each DRP had its
nsSNPGVH-encoded peptides filtered by predicted binding to six HLA class I
alleles specific to that DRP. Average number of peptides with binding affinity
labeled presented (<500 nM), and strongly presented (<50 nM) is shown.
where f(x) denotes the function of the curve and a and b are the
bounds on the x–axis, i.e., the lowest value of the IC50 recorded
and the cutoff chosen.
TISSUE EXPRESSION OF POLYMORPHIC PEPTIDES
Relative gene (and protein) expression level is a critical factor con-
tributing to HLA class I presentation of a peptide derived from the
gene (21). To investigate the tissue-specific expression of genes
incorporating presented peptides, software from the European
Bioinformatics Institute, Illumina Body Map, (http://www.ebi.ac.
uk/arrayexpress/experiments/E-MTAB-513/) was used to corre-
late presented peptides from the peptide library with relative gene
expression in different tissues represented in this software.
RESULTS
CREATION OF POLYMORPHIC PEPTIDES
Whole exomes of 9 SCT DRP were sequenced, identifying an aver-
age of 6,445 nsSNP between donors and recipients. To determine
the nsSNP that would be associated with possible mHA, pep-
tide sequences were generated that incorporated the polymorphic
amino acid at each position 1 to 9, in non-americ peptides using
the ANNOVAR software. Theoretically, this could yield nine dif-
ferent peptides for each SNP (Figure 1). However, a nsSNP near
either the 3′ or 5′ end of a sequence of a gene (N or C termi-
nus of a protein) would lead to fewer peptides. The ANNOVAR
output yielded on average 486,463 potential peptides encoded by
nsSNPs and presented by the six HLA molecules in these patients
(range: 1,043,514-366,426 peptides/DRP). This output was gener-
ally greater than the calculated possibilities since it also included
peptides resulting from splice variants of the various proteins bear-
ing SNP encoded amino acids. In all, these peptides constituted
the total pool of variant peptides, which may be immunogenic in
a DRP (Figure 2).
HLA-SPECIFIC ALLOREACTIVITY POTENTIAL
The 9-mer peptides bearing the polymorphic amino acid, with a
GVH vector were then analyzed for their binding affinities to the
individual HLA class I in each patient to determine the variant
peptides potentially presented to the donor T-cells. The IEDB-
SMM HLA class I binding prediction algorithm was utilized to
calculate the binding affinity of the peptide output from ANNO-
VAR, and to rank putative mHA for their ability to be presented
by individual HLA. After filtering for splice variants and duplicate
peptide representation in the dataset, a median of 18,396 (range:
1,926–72,294) peptides were identified that bound HLA-A, -B, and
-C with an intermediate affinity (IC50< 500 nM) in the nine DRP,
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and were designated as presented. Further, a median 2,254 (177–
21,548) peptides were predicted to bind MHC class I with a high
affinity (IC50< 50 nM) and were designated as strongly presented
(Figure 2). When separated by the donor type (MRD, n= 4, versus
URD, n= 5), the HLA-matched unrelated DRPs had a significantly
higher number of both presented and strongly presented peptides as
determined by IEDB SMM algorithm (P = 0.016; Mann–Whitney
U test) (Figure 3). The difference in the number of presented pep-
tides between unrelated and related donors corroborated the large
alloreactivity potential identified earlier in these donor types by
whole exome sequencing (14).
FIGURE 3 |Whole exome sequence variation and resulting HLA-binding
oligopeptides in MRD and URD. (A) Number of nsSNP, and the resulting
presented (IC50<500 nM) and strongly presented (IC50<50 nM) peptides
(GVH vector) presented by the HLA in each patient. (B) Same data
as in (A), presented with the y -axis changed to log-scale to better illustrate
the SNP to HLA-binding peptide ratio between MRD and URD. Significant
difference observed in the distribution of SMM-IEDB predicted presented
and strongly presented peptides between MRD and URD. Patients 2, 4, 16,
23 – MRD; patients 3, 5, 7, 8, 10 – URD SCT recipients.
To summarize the mass of information regarding the numerous
HLA-binding peptides and their binding affinities, the peptides
were ranked according to their binding affinity, that is, the IC50
values, and the distribution of their binding affinities was deter-
mined (Figure 4). For the analysis reported here, this operation
was performed without filtering duplicate peptide-HLA com-
plexes resulting from splice variants. Area under the curve (AUC;
nM•Peptide) for each DRP was then computed for peptides with
an IC50 up to 100 nM. Once again, marked differences were
observed in the calculated AUC between MRD and URD (Table 2).
This summarized measure hypothetically represents a HLA-specific
alloreactivity potential for each unique DRP, and may be consid-
ered as an example of the cumulative mHA differences observed
between the HLA-matched donors and recipients.
In a further analysis, when the reciprocal of the IC50 for
each peptide (a more direct numerical reflection of the bind-
ing affinity) was plotted for each peptide, a Power distribution
FIGURE 4 | Peptide-HLA complexes with IC50 values up to 100 nM
plotted in descending order of binding affinity. Depicting difference in
the number of peptide-HLA complexes (x -axis) and their IC50 values
(y -axis), for each DRP. Lower IC50 values correspond to greater binding
affinity between putative peptide and relevant HLA. IC50 distribution is
non-linear and described as a polynomial function of the second order,
forming a continuum. Marked difference observed between MRD and URD
(seeTable 2) for the AUC calculated from these plots.
Table 2 | HLA-specific alloreactivity potential.
Patient AUC (nM.Peptide)
2 0.0361*106
4 0.1191*106
16 0.0417*106
23 0.1906*106
3 2.5802*106
5 0.4751*106
7 2.2249*106
8 1.9886*106
10 0.3754*106
All the peptides with an SMM-IC50 of <100 nM were plotted in order of ascend-
ing IC50, and the area under the curve for the resulting graph for each patient
was determined (Formula 1). This value represents a summary measure of the
number of peptides with a high binding affinity and their binding affinities in each
DRP and is described by the dimensionless unit, nM.Peptide. See Figure 4 for
the individual plots. Unrelated DRP are shaded gray.
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Table 3 | Number of presented and strongly presented peptides predicted by the IEDB SMM and NetMHCpan algorithms.
Donor–recipient
pair
Number of
nsSNPGVH
SMM presented
peptide-HLA
SMM strongly
presented peptide-HLA
NetMHC presented
peptide-HLA
NetMHC strongly
presented peptide-HLA
Shared presented
peptide-HLA
2 4,446 1,926 250 3,883 1,376 1,332
4 4,448 5,412 825 3,962 885 2,441
16 3,290 2,111 177 1,071 427 417
23 3,657 13,456 705 787 118 534
3 7,227 72,294 21,339 7,242 2,509 4,881
5 6,572 30,730 2,254 2,759 538 1,865
7 6,725 58,209 21,548 5,231 2,178 2,931
8 6,573 65,298 19,275 4,831 2,000 2,445
10 9,203 18,396 2,283 5,002 989 2,065
The number of unique peptide-HLA complexes identified in silico for each donor-recipient pair. Last column represents number of unique peptides predicted to bind
the relevant HLA by both algorithms. Unrelated DRP are shaded gray. Presented (intermediate affinity HLA binding) and strongly presented (strong affinity HLA
binding) peptide-HLA complexes have IC50 of <500 and <50 nM, respectively.
was observed, analogous to T-cell clonal frequency distribution
previously reported (Figure S1 in Supplementary Material) (23).
VERIFYING HLA BINDING AFFINITY OF THE VARIANT PEPTIDE LIBRARY
IN UNIQUE DRP
To confirm the IEDB-SMM algorithm findings, a second peptide-
HLA binding affinity prediction tool, NetMHCpan was used to
interrogate the variant peptide libraries from the unique DRP
and its output compared with the IEDB SMM. The NetMHCpan
yielded a median of 3,962 peptides categorized as presented and
989 peptides as strongly presented in the nine DRP studied (MRD
versus URD, P = 0.063 and 0.11, respectively, Mann–Whitney U
test) (Table 3). The IEDB-SMM and NetMHCpan datasets were
then combined and unique peptide-HLA complexes predicted to
be presented by both algorithms determined (shared peptides).
The median number of shared unique peptides presented/DRP
was 2,065 (range: 417–4,881) (Table 3). A representative data
table depicting peptide sequences and respective IC50 values for
binding to a single HLA locus, in a patient, predicted by both
algorithms is given in Table S1 in Supplementary Material. Plot-
ting the IC50 of unique presented peptide-HLA complexes derived
utilizing both algorithms,demonstrated not only a very large num-
ber of complexes identified by both algorithms, but also that a
large proportion of these complexes were categorized as strongly
presented (Figure 5). Furthermore, a weak, but significant corre-
lation was identified between the IC50 predictions for both the
algorithms in the shared peptide-HLA complex datasets (N = 9,
median Pearson’s correlation coefficient R= 0.62,P < 0.01). Addi-
tionally, when the distribution of peptides presented on the three
class I HLA loci was examined, no discernable preference for par-
ticular HLA loci was observed in terms of likelihood of peptide
presentation (Figure S2A,B in Supplementary Material), except
for a possible HLA-C dominance in URD recipients in the SMM
algorithm.
TISSUE DISTRIBUTION OF PEPTIDES
For a peptide to be relevant in terms of its contribution to
GVHD risk, in addition to its potential for presentation on the
relevant HLA in a specific DRP, the relevant protein needs to
be expressed in the tissues. When the putative mHA (presented
peptides, IC50< 500 nM) were cataloged, according to the tissue-
specific expression of the genes they were derived from, most
organ systems had genes with potential mHA (Figure 6). Further,
although several antigens are expressed in organs, such as, colon,
liver, and lungs, frequent target organs for GVHD; a large number
of genes bearing potentially antigenic peptides are also expressed in
other organ systems such as the kidney and adipose tissue seldom
targeted by GVHD (Table S2 in Supplementary Material).
DISCUSSION
Allogeneic SCT represents a unique model system to study donor
T-cell responses to neo-antigens encountered in the recipient.
However, clinical transplantation is characterized by a vast reper-
toire of variant antigens, which in theory would result in a complex
expansion of the T-cell repertoire (24, 25). The findings reported
here provide a direct estimate of the antigenic variation, which may
be encountered by the donor cytotoxic T-cell (CTL) populations
following SCT. Starting from nsSNPs in the exomes of donors and
recipients, the reported analysis determined the resulting variant
nonameric peptides and gave an in silico estimate of the binding
affinity (reflected by the IC50) of these peptides to the relevant
HLA in the transplant recipients. The existence of this very large
library of immunogenic peptides in HLA-matched DRP, imme-
diately raises the question as to why only some and not all the
patients develop GVHD.
If all the peptides in this large library of potential mHA were
presented to non-tolerant T-cells, then GVHD would potentially
develop in all SCT patients, particularly with URD, where the mag-
nitude of immunogenic peptides is considerably larger than MRD.
Supporting this notion is the observation that development of
extensive chronic GVHD in patients is relatively common when
conventional immunosuppressive regimens are used. Further, our
findings offer a possible explanation for why most patients develop
GVHD, despite having HLA identical donors, and do so more fre-
quently when the donors are unrelated (26, 27). Alternatively, the
large magnitude of mHA between HLA-matched donors also gives
an insight into why patients undergoing HLA-mismatched trans-
plants such as haploidentical or mismatched URD transplants have
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FIGURE 5 | Unique peptide-HLA complexes (GVH vector) with
IC50<500 nM predicted by both SMM and NetMHCpan. Scatter plots
depict the IC50 for unique polymorphic peptide-HLA complexes predicted by
the two different algorithms studied. Each circle corresponds to a unique
peptide-HLA complex, with color depicting specific HLA. A large number of
patient-HLA-specific strong-binding peptides identified by both programs,
using SNP data derived from exome sequencing. Only shared peptide-HLA
complexes predicted to have an IC50< 500 nM by both algorithms included.
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FIGURE 6 |Tissue distribution of presented mHA with gene
expression. Number of genes coding for mHA (IC50<500 nM by
SMM algorithm) and expressed at a relative expression unit (REU)
value> 10. European Bioinformatics Institute Illumina Body Map was
used to correlate presented peptides with relative gene expression in
16 tissues. Several hundred genes per organ expressed have
nsSNPGVH, which may generate HLA binding peptides (SMM IEDB
dataset).
clinical outcomes, which are not dramatically different from those
of HLA-MR donors, that is, if appropriate GVHD prophylaxis
is used in the first few weeks of the transplant (28, 29). This
paradox may be understood, if one considers the mHA as the
targets for GVHD and HLA as the mediators of this phenomenon.
Thus, if the number of targets is relatively similar in HLA-matched
and haploidentical-related donor, and in the HLA-matched and -
mismatched URD transplant recipients; the difference introduced
by HLA mismatching is overcome by adjustments in the GVHD
prophylaxis regimens. One may postulate that even though thou-
sands of immunogenic peptides are present, the conditions at the
time of transplantation determine eventual outcome following
transplant, that is, whether tolerance will develop or GVHD ensue
following the initial interaction between recipient mHA-HLA
complexes and donor T-cells. As an example, when the protea-
some inhibitor bortezomib is added to the conditioning regimen,
by inhibiting peptide generation and consequently diminishing
antigen presentation to donor T-cells in the very first weeks of
the transplant, it reduces the risk of GVHD in URD SCT (6).
If the model outlined above is correct, then the enormous mag-
nitude of immunogenic peptides constituting the HLA-specific
alloreactivity potential will constitute an antigenic“pressure”upon
the non-tolerant donor T-cells when first encountered, influenc-
ing the evolving T-cell repertoire following SCT. This antigenic
pressure may be mitigated by agents, which influence either anti-
gen presentation (e.g., bortezomib) or the T-cell response (e.g.,
anti-thymocyte globulin, calcinuerin inhibitors, mycophenolate
mofetil, post-transplant cyclophosphamide). An observation from
this dataset that supports this hypothesis is that the frequency
distribution of the binding affinities of the peptides to the HLA
molecules follows the Power law (Figure S1 in Supplementary
Material). This frequency distribution is similar to the T-cell clonal
frequency distribution observed when T-cell clonality is measured
using high-throughput T-cell receptor β sequencing (23). This
suggests that the T-cell repertoire and clonal frequency emerging
after SCT may be proportional to the antigenic peptide-HLA bind-
ing affinities. Thus, peptides strongly bound to the HLA will elicit
a strong T-cell clonal response, if they engage a T-cell receptor
and appropriate co-stimulation is provided. And since the peptide
antigen binding affinities form a continuum, rather than discrete
clusters of high and low affinity, the T-cell repertoire frequency
similarly forms a continuum, described by the Power law. Another
conclusion to be considered from the non-discrete distribution of
peptide-HLA binding affinity is that other non-recipient derived
antigens, such as pathogen-associated peptides may also lie on this
continuum. This may result in cross-reactivity between autologous
antigens and pathogen-associated peptides (30). A manifestation
of this in the transplant setting is the triggering of GVHD or graft
rejection events by viral infections, such as cytomegalovirus or
human herpes virus 6 virus infections (31, 32).
Can these findings be used to develop a clinically relevant
model for allogeneic SCT? One possible explanation of the variant
outcomes following SCT is that post-transplant emergent T-cell
clones either develop tolerance to the many antigens encountered
or fail to do so depending on the milieu encountered in the host.
Early interventions, such as administration of anti-thymocyte
globulin, (33) bortezomib, or post-transplant cyclophosphamide
have a large impact on late post-transplant outcomes. Similar tol-
erance induction is observed following cellular interventions such
as regulatory T-cell infusion and conditioning, which up regulates
NK-T-cells at the time of SCT (34). This suggest that if a large
antigenic pressure from the HLA-specific alloreactivity potential
exists in all patients, then tissue injury and cytokine milieu at the
time of SCT may be influential in determining the development
of GVHD. Thus, if there is tissue injury following SCT, even if it is
sub-clinical, multiple antigens are presented, then in the absence of
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FIGURE 7 | A quantitative model for the development of GVHD. Whole
exome sequencing identifies all the nsSNP with a GVH vector, yielding a
putative alloreactivity potential, which may be a function (f ) of the cumulative
influence of these polymorphisms. This is represented as a series, listing the
sequence of polymorphic exome loci. Substituting individual nsSNPGVH in the
equation by peptide-HLA binding affinity (reciprocal of IC50)*relative
expression level of the gene bearing the nsSNPGVH (for each HLA molecule)
yields the HLA-specific alloreactivity potential, in this Re is the relative
expression of protein with nsSNPGVH and resulting peptides. In this series, the
expression, Rep1*(1/IC50P1-HLA-A1) for each specific peptide-HLA complex,
hypothetically represents the T-cell clone-specific AP. Multiple peptides
constituting this series then drive a proportional oligoclonal T-cell expansion in
GVHD, as many different mHA are presented by the HLA in an individual, the
final distribution conforming to the Power law. Since T-cell clonal expansion in
response to presented antigens may be influenced by factors such as tissue
injury, cytokine milieu, and immunosuppression intensity; the GVHD
likelihood, and its phenotype may in turn be determined not only by the
ubiquitous mHA but also by the tissue volume and its state
(inflammation/injury), and most importantly time at which organ
injury/inflammation occurs relative to T-cell infusion.
adequate immunosuppression, the T-cell repertoire that develops
results in the development of GVHD. On the other hand, if tissue
injury is minimized and there is adequate immunosuppression,
when the initial T-cell antigen-presenting cell interactions take
place, peripheral (or central) tolerance would emerge. Following
that, depending on the presence or absence of thymic tissue, T-
cell clones developing from infused stem cells may perpetuate this
process based on the prevailing T-cell population and target-tissue
antigen presentation, perhaps influenced by the state of tissue
injury (Figure 7). In such a model, inflammation provoked by the
acute GVHD initiated by infused donor-derived T-cells reacting to
recipient antigens is perpetuated in the form of “auto-reactivity”
by the T-cells, developing from infused stem cells in the absence of
normal thymic processing. This concept may not be novel in itself;
however, our model provides a biologically plausible explanation
reconciling mHA differences observed in HLA-matched DRP.
Correlating the variant peptides with tissue protein expression
levels, in our dataset, the immunogenic peptides appear to be uni-
formly distributed in the major organ systems of the body. This
raises the following question: why do solid organ transplant recip-
ients develop rejection, but GVHD does not commonly affect
most such organs, such as the kidney and heart? The data pre-
sented in this paper suggest a possible answer to this question
if the above quantitative model of immunobiology of transplan-
tation is considered. Hypothetically, in the days following SCT,
when the infused donor T-cells encounter widespread variant
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immunogenic recipient antigens in inflamed tissues with a large
tissue interface for T-cell antigen-presenting cell interaction, i.e.,
skin, GI mucosa, liver, and lungs, there is a corresponding poly-
clonal T-cell allo-immune response, which may result in GVHD
affecting the targeted organs. In contrast, the relatively smaller
tissue interface in the absence of direct injury, in organs such as
the heart and kidney, do not trigger an immunogenic response
in the face of an ongoing, competing oligoclonal T-cell response
elicited by the larger organ systems with injury. When solid organ
transplantation is performed, tissue injury even if sub-clinical,
in the transplanted organ resulting from the transplant proce-
dure serves as the injury stimulus triggering graft rejection. Based
on these data, a theoretical model has been proposed to investi-
gate the notion of alloreactivity potential and its relationship with
GVHD onset and propagation over time as in a“chaotic dynamical
system” (35).
A potential therapeutic application of this analysis would be
the ability to “titrate” the intensity of immunosuppressive therapy
in the peri-transplant period based on the magnitude of the HLA-
specific alloreactivity potential. This study supports the need for
intensive immunosuppression in patients undergoing URD allo-
geneic SCT, making this algorithm a useful analysis for treatment
planning (36). For example, if a patient has a high number of
predicted mHA and these are over-represented in lung tissue, ther-
apies can be specifically tailored for that patient and symptoms
of lung GVHD treated more promptly. Alternatively, large-scale
protein expression studies by Ponten et al. concluded that most
proteins are expressed in most tissues, although in varying quanti-
ties (37). This raises the question of which parameter plays a larger
role in peptide presentation by MHC class I HLA: the absolute
molar amount of protein expressed in a tissue, or the binding
affinity for a particular peptide; in theory, it may be a combination
of the two (Figure 7).
As with any in silico work, this work can only be considered pre-
liminary and the peptide-HLA class I combinations predicted in
our work, will need experimental verification. Acknowledging this
limitation, it should be noted that the accuracy of these algorithms
has been reviewed and they have been found to be useful pre-
dictors of HLA presentation. A similar large number of peptides
binding HLA in EBV-transformed B cell lines have been identified
when directly characterizing the “ligandome” presented by these
cells (38). Further, in a vaccinia virus challenge mouse model, the
NetMHC algorithm was able to predict epitopes responsible for
95% of the CTL response with an IC50 threshold of <500 nM
(39). Similarly, Armistead et al. found that with an IC50 thresh-
old of <500 nM, all peptides predicted by SMM-IEDB algorithm
bound HLA-A 0201 in their assays (40). To put our data in con-
text, a database from all known nsSNPs that had been deposited
in NCBI’s dbSNP database is presented in Figure 2 and is labeled
as all possible mHA in human beings (22, 41). In light of these
findings, it is not at all surprising that we find a large library of
immunogenic mHA in each DRP, and there may exist a similar
alloreactivity potential mediated by HLA class II.
In conclusion, the findings reported here demonstrate that
whole exome sequencing, followed by in silico peptide genera-
tion and HLA binding affinity determination reveal a large and
previously unmeasured HLA-specific alloreactivity potential. This
potential is predictably larger in patients undergoing URD SCT
and mirrors previously described T-cell clonal frequency distrib-
ution. We posit that these methodologies may be used to develop
mathematical models to better understand the immunopathol-
ogy of SCT from both HLA-matched and mismatched donors
and may in the future allow more precise titration of the
immunosuppression intensity in individual transplant recipients.
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